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there are strategic locations not mounted with rubs and identified 22
such locations.
4. HH education program and daily checklist for health care assistants
(HCAs): This is implemented by the ICLNs for the reduction in compliance
among HCAs is the highest.
After implementing the four programs, compliance increased to 83% in 2012
(n Z 1743, CI 81e85%) which is significant (p < 0.01) compared to
2009e2011. Alcohol hand rub consumption showed a similar trend in 2012,
increasing from 8.1L per 1000 patient-days in 2011 to 9.1L in 2012.
To overcome Hand Hygiene campaign fatigue it is important to be innovative
and adopting principles in management science. Results showed that
optimizing the collaboration of ICLN will bridge the implementation gaps
between the Infection Control Team and the frontline staff that significantly
improve hand hygiene compliance.KS 19
INFECTION CONTROL IN MULTI-DRUG RESISTANT ORGANISMS (MDROS)
Chun-Ming Lee, MD, PhD FCCP, DTCD(UK), DTM&H(UK). Chairman of
Infection Control Society of Taiwan, Mackay Memorial Hospital, Taipei,
TaiwanMultidrug-resistant organisms (MDROs),
including gram-positive coccus (GPC) such as
MRSA, VRE, VISA, VRSA and certain gram-
negative bacilli (GNB) such as ESBL, carbape-
nem-resistant enterobacteriaceae (CRE)
,CRPA and CRAB had important infection con-
trol implications. Although transmission of
MDROs ismost frequently documented in acute
care facilities, all healthcare settings affected
by the antimicrobial resistance rates are also
strongly correlatedwith hospital size, tertiary-
level care, and even facility type (e.g., LTCF).Emergence and transmission of antimicrobial-resistant microbes increased
lengths of stay, costs, patient mortality and legal problem also had been
associated with MDROs but the options for treating patients with these
infections are often extremely limited.
The various types of intervention used to control or eradicate MDROs may be
grouped into four major categories. These include diminishing healthcare
associated infections by different care bundles such as for CLABSI, UTI and
VAT, proper antibiotic stewardship policy (ASP), basic and advancedenvironment cleaning and hospital active surveillance. Using a combination
of interventions, MDROs in endemic, outbreak, and non-endemic settings
have been brought under control.
Despite the volume of literature, an appropriate set of evidence-based
control measures that can be universally applied in all healthcare settings
has not been definitively established. The approaches to prevent and
control of these pathogens need to be tailored to the specific needs of each
population and individual institution. Antimicrobial resistance and its
global spread, threatens the continued effectiveness of many medicines
used today to treat the sick, while at the same time it risks jeopardizing
important advances being made against major infectious killers. The
prevention and control of MDROs is a national priorityeone that requires
all healthcare facilities and all related government departments to assume
responsibility.
KS 20
WHONET e 25 (AND 50) YEARS ON
Thomas F. O’Brien, MD, John Stelling, MD, MPH. Brigham and Women’s
Hospital, WHO Collaborating Centre for Surveillance of Antimicrobial
Resistance, Boston, United StatesRoutine clinical microbiology laboratories
generate daily a detailed window into evolving
microbial populations worldwide. Our labora-
tory first createdmainframe-based routines for
the management of analysis of these data in
1964 for our own facility with a special focus on
antimicrobial susceptibility tests results and
the appearance and characterization of resis-
tant pathogens. In the 1970s, we initiated
national and international collaborations for
monitoring resistance. The introduction of per-
sonal computers in the 1980s permitted collab-
orating laboratories to enter and analyze their
own data for the first time, and our facility wasdesignated a WHO Collaborating Centre for Surveillance of Antimicrobial
Resistance in 1986. The name WHONET was given to the software package in
1989with the introduction of a software configurationmodulewhich permitted
the independent dissemination of our software worldwide. Since that time,
WHONET use has grown to support local, national, and global infection and
antimicrobial resistance surveillance activities in over 2,300 human, animal,
and food laboratories in over 110 countries worldwide. A current priority is
assisting the World Health Organization with implementation of the Global
Action Plan on Antimicrobial Resistance.
